Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.

Source:http://linkedlifedata.com/resource/pubmed/id/17019715

Int. J. Cancer 2006 Dec 15 119 12 2784-94

Download in:

View as

Triples

General Info

PMID
17019715